Compare GSL & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSL | MPLT |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | Greece | United States |
| Employees | 7 | 133 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | N/A | N/A |
| Metric | GSL | MPLT |
|---|---|---|
| Price | $41.84 | $12.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $44.00 | $32.67 |
| AVG Volume (30 Days) | 304.3K | ★ 1.3M |
| Earning Date | 05-18-2026 | 05-28-2026 |
| Dividend Yield | ★ 6.34% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.49 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.28 | $9.10 |
| 52 Week High | $44.69 | $40.43 |
| Indicator | GSL | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 49.23 | 28.72 |
| Support Level | $37.00 | $11.56 |
| Resistance Level | $42.70 | $20.73 |
| Average True Range (ATR) | 1.10 | 2.03 |
| MACD | -0.26 | -1.11 |
| Stochastic Oscillator | 3.93 | 11.12 |
Global Ship Lease Inc is a containership owner, leasing ships to container shipping companies under industry-standard, fixed-rate time charters. Its fleet comprises mid-size Post-Panamax, Cypress, and smaller containerships, which tend to serve the faster-growing non-Mainlane and intra-regional trades, collectively representing the majority of the containerized trade volume globally. The company generates revenue from chartering its vessels to liner companies.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.